Skip to Content
UW Health SMPH
American Family Children's Hospital
DONATE Donate
SHARE TEXT
Julie E. Chang, MD close
FeBCWunywYQ
Julie E. Chang, MD
 

Julie E. Chang, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Chang joined the University of Wisconsin as an Assistant Professor in 2007. After graduating from Indiana University School of Medicine, she completed her internal medicine residency and hematology and oncology fellowships at the University of Wisconsin. Dr. Chang treats a wide range of cancers, but has special interest in lymphoma and complications of cancer involving the central nervous system. She is actively participating in further developing the Lymphoma Research Program at the University of Wisconsin Carbone Cancer Center.

Specialties

Hematology

Medical Oncology

UW Health Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

Other Locations

Richland Hospital (Richland Center)
(608) 647-6321 |  Map
Richland Hospital (Richland Center)
(608) 647-6321 |  Map

Hospital Affiliation(s)

University of Wisconsin Hospital and Clinics (primary)
Veterans Hospital - Wm. S. Middleton Memorial (secondary)

Languages Spoken

English
Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Internal Medicine
Hematology
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School Indiana University School of Medicine, Indianapolis, IN, 2000

Programs & Conditions

Research

Dr. Chang is part of the UW Lymphoma Research Program, through which multiple clinical trials are focusing on developing improved treatment options for patients with lymphoma. Dr. Chang's research interests include lymphoma, experimental therapeutics and complications of cancer involving the central nervous system.


PubMed Articles
Chang JE Li H Smith MR Gascoyne RD Paietta EM Yang DT Advani RH Horning SJ Kahl BS . Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood. 2014 Mar 13;123(11):1665-73
[PubMed ID: 24458437]
Chang JE Kahl BS . PI3-kinase inhibitors in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2014 Mar;9(1):33-43
[PubMed ID: 24390602]
Lake W Chang JE Kennedy T Morgan A Salamat S Ba┼čkaya MK . A case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics. Neurosurgery. 2013 Jun;72(6):960-70; discussion 970
[PubMed ID: 23685504]
Chang JE Kahl BS . Bendamustine for treatment of chronic lymphocytic leukemia. Expert Opin Pharmacother. 2012 Jul;13(10):1495-505
[PubMed ID: 22663160]
Chang JE Kahl BS . Bendamustine: more ammunition in the battle against mantle cell lymphoma. Leuk Lymphoma. 2012 Jul;53(7):1249-50
[PubMed ID: 22220986]
Chang JE Kahl BS . Current status of targeted therapies for mantle cell lymphoma. Drugs. 2011 Dec 3;71(17):2307-26
[PubMed ID: 22085387]
Leal T Chang JE Mehta M Robins HI . Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment. Curr Cancer Ther Rev. 2011 Nov;7(4):319-327
[PubMed ID: 23251128]
Chang JE Peterson C Choi S Eickhoff JC Kim K Yang DT Gilbert LA Rogers ES Werndli JE Huie MS McFarland TA Volk M Blank J Callander NS Longo WL Kahl BS . VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol. 2011 Oct;155(2):190-7
[PubMed ID: 21848883]
Lepeak LM Yang DT Chang JE . Extranodal NK/T-cell lymphoma presenting with primary cardiac involvement. Hematol Rep. 2011 Aug 31;3(2):e9
[PubMed ID: 22184541]
Cassaday RD Malik JT Chang JE . Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn's disease: a case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):289-92
[PubMed ID: 21658658]
Visco C Hoeller S Malik JT Xu-Monette ZY Wiggins ML Liu J Sanger WG Liu Z Chang J Ranheim EA Gradowski JF Serrano S Wang HY Liu Q Dave S Olsen B Gascoyne RD Campo E Swerdlow SH Chan WC Tzankov A Young KH . Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component. Am J Surg Pathol. 2011 Feb;35(2):177-89
[PubMed ID: 21263238]
Chang JE Seo S Kim KM Werndli JE Bottner WA Rodrigues GA Sanchez FA Saphner TJ Longo WL Kahl BS . Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study. Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):379-84
[PubMed ID: 21030351]
Chang JE Medlin SC Kahl BS Longo WL Williams EC Lionberger J Kim K Kim J Esterberg E Juckett MB . Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leuk Lymphoma. 2008 Dec;49(12):2298-307
[PubMed ID: 19052977]
Chang JE Juckett MB Callander NS Kahl BS Gangnon RE Mitchell TL Longo WL . Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. Clin Lymphoma Myeloma. 2008 Jun;8(3):153-8
[PubMed ID: 18650178]
Chang JE Khuntia D Robins HI Mehta MP . Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol. 2007 Nov;5(11):894-902, 907-15
[PubMed ID: 18185489]
Chang JE Robins HI Mehta MP . Therapeutic advances in the treatment of brain metastases. Clin Adv Hematol Oncol. 2007 Jan;5(1):54-64
[PubMed ID: 17339829]